Multiple Myeloma News

AbbVie and the International Myeloma Foundation Partner to Study Role of a Genetic Mutation in Multiple Myeloma (March 28, 2018)

AbbVie a research and development-based global biopharmaceutical company, and the International Myeloma Foundation (IMF) today announced they have entered into a collaboration to conduct a landmark retrospective chart review study to better understand... Continue Reading

CRISPR Enhances Cancer Immunotherapy (March 14, 2018)

Gene editing expands reach of therapeutic T cells, in mice CancerConnect News: Last year, the Food and Drug Administration approved the first cellular immunotherapies to treat cancer. These therapies involve collecting a patient’s own immune cells —... Continue Reading

Darzalex-Effective Treatment for Smoldering Multiple Myeloma (March 7, 2018)

CancerConnect News: The use of Darzalex (daratumumab) in smoldering myeloma may be effective in delaying the time to disease progression. These results were presented at the 2017 annual meeting of the American Society of Hematology (ASH). Multiple myeloma... Continue Reading

Kyprolis Improves Survival in Recurrent Multiple Myeloma (February 8, 2018)

CancerConnect News: The addition of Kyprolis® (carfilzomib) to the standard treatment regimen, Revlimid® (lenalidomide) and dexamethasone, improves survival for patients with multiple myeloma whose disease progressed or recurred following prior therapies.... Continue Reading

Diagnosed with Multiple Myeloma: 10 Tips on How to Get The Most From Your Doctor (February 7, 2018)

1) Choose Your Doctor Carefully Hematologists and oncologists are the primary doctors involved with multiple myeloma and often work in collaboration with stem cell transplant physicians. Pick your primary hematologist/oncologist carefully, rely on people... Continue Reading

Xgeva Approved for The Treatment of Multiple Myeloma (January 17, 2018)

CancerConnect News: The US Food and Drug Administration (FDA) has expanded the approval of Xgeva (denosumab) for the prevention of skeletal-related events in patients with bone metastasis from multiple myeloma. In multiple myeloma, plasma cells infiltrate... Continue Reading

Addition of Darzalex™ Improves Outcomes in Newly Diagnosed Multiple Myeloma (December 13, 2017)

The addition of Darzalex (daratumumab) to the standard treatment combination consisting of Velcade (bortezomib), melphalan, and prednisone (VMP) reduces disease progression or death by 50%, among patients with newly diagnosed multiple myeloma who are... Continue Reading

FDA Adds Two Roche Multiple Myeloma Studies Evaluating Checkpoint Inhibitors to List of Partial Clinical Holds Over Safety Concerns (September 25, 2017)

Alarmed that an imbalance in deaths among patients taking a combination of Keytruda (pembrolizumab) with Celgene’s Pomalyst and Revlimid could represent a threat in that whole class of checkpoint comboinations, the FDA has added two Tecentriq (atezolizumab)... Continue Reading

Four-Year Follow-up with Empliciti Plus Revlimid in Patients with Advanced Multiple Myeloma Shows Long-term Beneift (July 13, 2017)

Four-year follow-up data from the Phase 3 ELOQUENT-2 clinical trial in which Empliciti (elotuzumab) plus Revlimid (lenalidomide) continued to demonstrate effectiveness in patients with relapsed/refractory multiple myeloma compared to patients treated... Continue Reading

Latest Multiple Myeloma News By Stage


Recurrent Multiple Myeloma

Sorry, there are no articles available for this cancer stage.

More Recurrent Multiple Myeloma

Stage I/Smoldering Myeloma Multiple Myeloma

Sorry, there are no articles available for this cancer stage.

More Stage I/Smoldering Myeloma Multiple Myeloma

Stages II-III Multiple Myeloma

Sorry, there are no articles available for this cancer stage.

More Stages II-III Multiple Myeloma